Sarmen Sarkissian, M.D.
Sarmen Sarkissian, M.D., is inspired by his patients’ perseverance and relishes the daily challenges that come with providing them the best care possible, with particular importance placed on communicating with them clearly. Dr. Sarkissian was first drawn to cancer care by his love of pharmacology and molecular biology — and his interest in applying advances in science to patient care. Accordingly, he places a premium on providing access to innovative new therapies through clinical trials.
Dr. Sarkissian pursued his medical training at University of California San Diego, a residency at University of Southern California and a fellowship at University of California Irvine. His contributions to the research literature include an overview of BTK inhibitors, promising investigative drugs for chronic lymphocytic leukemia and a case report detailing MGRS — a side effect of treatment that strikes the kidney.
Fluent in Armenian, Dr. Sarkissian enjoys reading and spending time with his family.
2014, American Board of Internal Medicine
2017, Hematology & Oncology, American Board of Internal Medicine
2011, M.D., University of California, San Diego, La Jolla, CA
2006, B.S., Chemistry, University of California, Los Angeles, Los Angeles, CA
2016, Clinical Fellow, Hematology-Oncology, Chao Family Comprehensive Cancer Center, University of California, Irvine, Irvine, CA
2013, Intern and Resident, Internal Medicine, Los Angeles County+USC Medical Center, University of Southern California, Los Angeles, CA
2021-present, Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research, City of Hope, Long Beach, CA
2017-2021, Hematologist-Oncologist, Pacific Shores Medical Group, Long Beach, CA
2006, Departmental Honors Upon Graduation, Department of Chemistry and Biochemistry, University of California, Los Angeles, CA
2006, Scholarship and Award for Distinguished Effort as a Hospital Volunteer, University of California, Los Angeles Medical Center Auxilliary, Los Angeles, CA
2014, American Association of Cancer Research
2014, American Society of Hematology
2014, American Society of Clinical Oncology
2011, American College of Physicians
- Sarkissian S, Tran P, Chao J, et al. PD-1 and PD-L1 as Emerging Therapeutic Targets in Gastric Cancer: Current Evidence; Gastrointestinal Cancer: Targets and therapy. 2017; 7(1): 1-11
- Sarkissian S, Seery T. Acute Liver Failure from Anti-PD-1 Antibody Nivolumab in a Patient with Metastatic Lung Squamous Cell Carcinoma; Austin Oncology. 2016; 1(1):1-3
- Sarkissian S, Kahlon K, Walavalkar V, et al. Renal Manifestations of Alternate Complement Pathway Dysregulation. Journal of Urology and Nephrology 2015; 2(1): 1-4
- Sarkissian S, Amzajerdi A, Rezk S. Hemophagocytic lymphohistiocytosis in a patient with Extranodal NK Lymphoma, Nasal type, complicated by bone marrow and central nervous system involvement. The New Armenia Medical Journal 2017; 11(2) 6-11